Physician

Nahida Islam, M.D.

According to 2025 Medicare claims, Nahida Islam, M.D. (NPI: 1568669646) practices medical oncology in the Worcester, MA market, with the plurality of this provider's patient population coming from Worcester, MA. This provider's primary affiliated billing organization is RELIANT MEDICAL GROUP, INC (NPI: 1720017528; TIN: 042472266) and primary practice location at 01606-2714. Islam is affiliated with the UMASS Memorial Accountable Care Organization, INC. (ACO ID: A2598) and Reliant Medical Group, Inc. (ACO ID: D0218), participating under both the MSSP and REACH models.

Islam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 236 traditional Medicare patients, billed 620 HCPCS/CPT codes, and received $51,859 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 672 prescription claims across 107 beneficiaries totaling $2,782,370 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 21 claims. Open Payments data shows 3 records totaling $5,923. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $297,290 to $2,782,370. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,529 and ending at $197.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	256	606	$44,851
2016	292	831	$58,544
2017	336	883	$65,813
2018	346	884	$65,075
2019	394	955	$74,564
2020	325	881	$68,383
2021	333	874	$78,950
2022	314	767	$65,525
2023	262	698	$58,550
2024	236	620	$51,859

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	80	477	$297,290
2016	105	805	$911,808
2017	133	843	$1,542,635
2018	132	867	$1,871,488
2019	151	779	$1,407,393
2020	121	769	$1,845,701
2021	119	739	$2,415,498
2022	118	660	$2,552,077
2023	107	630	$2,372,738
2024	107	672	$2,782,370

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	18	$1,156
2020	N/R	51	$2,544
2021	N/R	30	$1,163
2022	N/R	21	$686
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	36	36	$136
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	28	28	$133
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	48	75	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	145	411	$74
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	32	38	$48

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	952	$651,575
Xtandi	Enzalutamide	32	960	$400,931
Pomalyst	Pomalidomide	16	448	$353,826
Tagrisso	Osimertinib Mesylate	20	600	$341,007
Jakafi	Ruxolitinib Phosphate	12	360	$207,862

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$292	Galvanize Therapeutics, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$5,631	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nahida Islam, M.D.?

Tedicare shows public-source Medicare data for Nahida Islam, M.D. (NPI 1568669646), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nahida Islam, M.D. have ACO affiliation data?

Nahida Islam, M.D. is shown with ACO affiliation data for UMASS Memorial Accountable Care Organization, INC. (MSSP, ACO ID A2598) and Reliant Medical Group, Inc. (REACH, ACO ID D0218).

What billing organization is linked to Nahida Islam, M.D.?

Nahida Islam, M.D. is linked to RELIANT MEDICAL GROUP, INC (billing NPI 1720017528) in the available physician profile data.

Does Nahida Islam, M.D. have Open Payments data?

Nahida Islam, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.